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ABSTRACT  
 
The extracellular matrix (ECM) is a complex meshwork of insoluble fibrillar proteins and signaling 
factors interacting together to provide architectural and instructional cues to the surrounding cells. 
Alterations in ECM organization or composition and excessive ECM deposition have been observed in 
diseases such as fibrosis, cardio-vascular diseases, and cancer. We provide here optimized protocols to 
solubilize ECM proteins from normal or tumor tissues, digest the proteins into peptides, analyze ECM 
peptides by mass spectrometry, and interpret the mass spectrometric data. In addition, we present here 
two novel R-script-based web tools allowing rapid annotation and relative quantification of ECM 
proteins, peptides, and intensity/abundance in mass spectrometric data output files. We illustrate this 
protocol with ECMs obtained from two pairs of tissues which differ in ECM content and cellularity; 
triple-negative breast cancer and adjacent mammary tissue, and omental metastasis from high-grade 
serous ovarian cancer and normal omentum. The complete proteomics dataset generated in this study 
has been deposited to the public repository ProteomeXchange with the dataset identifier: PXD005554. 
 
KEYWORDS: Extracellular Matrix, Matrisome, Collagens, Microenvironment, Hydroxylation, Mass-
spectrometry-based proteomics  
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INTRODUCTION 
 
The extracellular matrix (ECM), a complex and dynamic meshwork of cross-linked proteins, is a 
fundamental component of multicellular organisms 1. The ECM provides architectural, mechanical, and 
biochemical signals interpreted by cell-surface receptors, and orchestrates cellular processes such as 
adhesion, migration, proliferation, survival, and differentiation 2,3. Alterations in the composition and 
organization of the ECM cause or accompany the development of diseases including fibroses, cardio-
vascular diseases, and cancers 4–6.  
Because of its complexity and insolubility, the ECM has been difficult to analyze biochemically and, 
until recently, it was not possible to obtain a detailed understanding of its composition 7. We have 
previously developed a proteomic pipeline to characterize the composition of in vivo ECMs and have 
shown that any given tissue or tumor includes well over 100 ECM and ECM-associated proteins and 
that characteristic differences can be detected between different tissues or tumors 8–10. One critical step 
in this proteomic approach was the development of a method to enrich ECM proteins from tissues and 
tumors. To do so, we and others devised decellularization methods that deplete intracellular proteins 
and permit the enrichment of ECM proteins 8,11–20. A second critical step of the approach was the 
identification and annotation of the ECM components, or ‘matrisome’, in large proteomic datasets. To 
this end, we devised a computational approach and defined the in silico matrisome as the ensemble of 
genes encoding core ECM proteins (ECM glycoproteins, collagens, and proteoglycans) and ECM-
associated proteins (these are proteins structurally resembling ECM proteins, ECM remodeling 
enzymes and secreted factors including growth factors) 8,21.  
 
As the details of the methods applied in the various analyses of ECM proteins using mass-
spectrometry-based proteomics in our laboratories and others vary somewhat, we have now explored 
the impact of variations in the protocols. We provide here updated protocols for 1) digestion of ECM 
proteins into peptides, 2) analysis of ECM peptides by mass spectrometry, and 3) interpretation of mass 
spectrometric data. We illustrate the protocols with results obtained on the ECM from two sets of 
tissues that differ significantly in their ECM content and cellularity: human triple-negative breast 
cancer samples and adjacent breast tissue, and omental metastases from high-grade serous ovarian 
cancer (HGSOC) and normal omentum (Figure 1A). The optimized protocols presented here make the 
	 4	
comprehensive characterization of the composition of the ECM accessible to a broad range of scientists 
and should help enhance the identification of disease biomarkers and novel therapeutic targets. 
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MATERIALS AND METHODS 
 
Samples 
Patient samples were kindly donated by women with high-grade serous ovarian cancer (HGSOC; n=2) 
or triple-negative breast cancer (TNBC; n=2) undergoing surgery at Barts Health NHS Trust between 
2010 and 2014. Tissues deemed by a pathologist to be surplus to diagnostic and therapeutic 
requirements were collected together with associated clinical data under the terms of the Barts Gynae 
Tissue Bank (HTA licence number 12199. REC no: 10/H0304/14), and Barts Breast Cancer Tissue 
Bank (HTA license number 12199. REC no: 15/EE/0192). In both cases TNBC and HGSOC samples 
are described as containing tumor cells and desmoplasia, whilst normal or adjacent samples are 
described as having no obvious tumor cell infiltration or desmoplasia (Supplementary Table S1A). 
Masson's trichrome staining was performed according to standard procedures to evaluate the ECM 
content and cellularity of all four tissue types. 
 
Enrichment for ECM components 
ECM proteins were enriched from frozen whole tissue or tumor sections (20 x 30 μm sections, 
approximately 40-50 mg of tissue) as previously described 15. In brief, tissue sections were resuspended 
in the cytosolic ("C") buffer of the CNMCS compartmental protein extraction kit (Millipore) and 
disrupted by vortexing. The samples were then incubated in a series of buffers to remove sequentially 
nuclear proteins (buffer "N"), membrane proteins (buffer "M"), and cytoskeletal proteins (buffer "CS"), 
according to the manufacturer's instructions and our previous protocol 15. The remaining insoluble 
pellet is enriched for ECM proteins. Note that the subsequent steps can also be conducted on ECM-
enriched samples prepared according to other methods 11-20. 
 
ECM protein solubilization  
ECM-enriched samples were solubilised in 8M urea, 20mM HEPES containing Na3VO4 (100mM), NaF 
(0.5M), β-Glycerol Phosphate (1M), Na2H2P2O7 (0.25M). Samples were vortexed for 30 seconds and 
held on ice prior to sonication at 50 % intensity, 3 times for 15 seconds, on ice. These resuspended and 
partially solubilized ECM-enriched samples were either directly digested into peptides as described 
below ("crude" ECM samples), or were centrifuged at 20,000 g for 10 min at 5oC, and the supernatant 
recovered to protein low-bind tubes. This fraction will further be referred to as the urea-soluble 
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fraction. Protein concentration of the urea-soluble fraction was estimated using BCA assay and 80 μg 
of protein was digested into peptides as described below. The post-centrifugation urea-insoluble pellet 
was resuspended in 2M urea and proteins were digested as described below.  
 
ECM protein digestion into peptides 
Disulphide bonds were reduced by adding 5mM dithiothreitol to the samples for a 1-hour incubation 
under agitation at room temperature. Free cysteines were alkylated by adding iodoacetamide at a final 
concentration of 8.3mM to the samples for a 1-hour incubation under agitation at room temperature in 
the dark. After diluting to 2M urea, 20mM HEPES, samples were deglycosylated with 1500 units of 
PNGaseF (New England BioLabs, Ipswich, MA) by incubation at 37°C for 2 hours under agitation. 
Samples were pre-digested with 1.6 μg of Lys-C (Pierce) and incubated at 37°C for 2 hours under 
agitation, and digested with bead-immobilized trypsin (40 μL of beads per 250 μg of protein; Pierce) 
for 16 h at 37oC under agitation. Samples were acidified with trifluoroacetic acid (TFA, 1% v/v), 
centrifuged at 2,000 g for 5 minutes at 5oC. Supernatants were transferred to clean microcentrifuge 
tubes on ice. Glygen TopTips were equilibrated with 100 % LC-MS-grade acetonitrile (ACN) and then 
washed with 99 % H2O (+ 1 % ACN, 0.1 % TFA) prior to loading the peptide samples. Samples were 
washed with 99% H2O (+ 1 % ACN, 0.1 % TFA), and desalted peptides eluted with 70/30 ACN/H2O + 
0.1 % TFA. Desalted peptides were dried and stored at -20oC. 
 
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) 
Equal volumes of each sample, corresponding to approximately 100ng of material, were initially 
analyzed via LC-MS/MS, and the total numbers of peptides identified and the sum of the intensities of 
the precursor ions was used as a normalization metric to determine equivalent peptide amounts. 
Peptides were separated by reversed-phase HPLC using an EASY-nLC1000 (Thermo Scientific) using 
a pre-column (made in house, 6 cm of 10 µm C18) and a self-pack 5 µm tip analytical column (12 cm 
of 5 µm C18, New Objective) over a 140-minute gradient before nanoelectrospray using a QExactive 
mass spectrometer (Thermo).  Solvent A was 0.1% formic acid and solvent B was 80% MeCN/0.1% 
formic acid.  The gradient conditions were 0-10% B (0-5 min), 10-30% B (5-105 min), 30-40% B (105-
119 min), 40-60% B (119-124 min), 60-100% B (124-126 min), 100% B (126-136 min), 100-0% B 
(136-138 min), 0% B (138-140 min).  The mass spectrometer was operated in a data-dependent mode. 
The parameters for the full MS scan were:  resolution of 70,000 across 350-2000 m/z, AGC 3e6, and 
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maximum IT 50 ms. The full MS scan was followed by MS/MS for the top 10 precursor ions in each 
cycle with a normal collision energy of 28 and dynamic exclusion of 30 seconds.   
 
Off-line fractionation of peptides by reversed-phase chromatography at high pH  
Equivalent peptide amounts were fractionated via high-pH reversed-phase HPLC. Peptides were 
resuspended in 50uL buffer A (10mM NH4HCO3, pH8) and separated on a 4.6mm x 250 mm 
300Extend-C18, 5um column (Agilent) using an 80-minute gradient from 1% to 100% buffer B (90% 
MeCN, 10mM NH4HCO3, pH8) at a flow rate of 1ml/min. Fractions were collected over 75 minutes at 
1-minute intervals beginning at 5 minutes after the start of the gradient. The fractions were 
concatenated into 15 fractions non-contiguously (1+16+31+46+61, 2+17+32+47+62, etc.) 22. The 
fractions were brought to near dryness in a speed-vac (Thermo Scientific). Each fraction was 
resuspended in 80uL 0.1% formic acid and 4uL was analyzed via LC-MS/MS as described above using 
the same 140-minute gradient.  
 
Protein identification 
Raw mass spectral data files (.raw) were searched using Proteome Discoverer (Thermo Scientific) and 
Mascot version 2.4.1 (Matrix Science) using the SwissProt Homo sapiens database containing 20199 
entries. Mascot search parameters were: 10 ppm mass tolerance for precursor ions; 15 mmu for 
fragment-ion mass tolerance; 2 missed cleavages of trypsin; fixed modification was 
carbamidomethylation of cysteine; variable modifications were oxidized methionine, deamidation of 
asparagine, pyro-glutamic acid modification at N-terminal glutamine and hydroxylation of lysine and 
proline (see Results section). Only peptides with a Mascot score greater than or equal to 25 and an 
isolation interference less than or equal to 30 were included in the data analysis. The average false 
discovery rate was 0.0074 (ranging from 0.0032 - 0.0144). For each protein, total precursor ion 
intensity (further referred to as "peptide intensity") was calculated as the sum of MS1-precursor-ion-
peak areas for all identified peptides of the given protein. Confidently identified proteins were further 
annotated as being part of the extracellular matrix as previously defined 8,21 and using the novel tool 
Matrisome Annotator presented in this publication (see Results section).  
The raw mass spectrometry data have been deposited to the ProteomeXchange 23 via the PRIDE partner 
repository 24 with the dataset identifier: PXD005554.  
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[Note to the editor and reviewers: The raw mass spectrometry data will become publicly available 
upon acceptance of the paper. During the evaluation of the manuscript, the reviewers can access the 
raw mass spectrometry by login to the PRIDE website using the following credentials: username: 
reviewer45448@ebi.ac.uk and password: nOivfFjG.].  
 
  
	 9	
RESULTS 
 
Optimization of methods to solubilize and digest ECM proteins 
We initially devised a method that consisted of enrichment of tissue samples for ECM proteins, partial 
solubilization in 8M urea and digestion of this "crude" ECM extract into peptides. Using this protocol, 
the most abundant proteins identified were fibrillar collagens 8. We hypothesized that the abundance of 
fibrillar collagens could prevent the identification of other ECM or ECM-associated proteins present in 
lower abundance. To test this, we compared the original method with a method consisting of digesting 
only the urea-soluble fraction of ECM-enriched samples (Figure 1B). We observed that for the four 
tissues analyzed (breast cancer and adjacent breast tissue samples, and omentum and ovarian-cancer-
derived omental metastasis samples; n=2 for each sample type), the abundance of ECM peptides 
(Figures 2A and B, upper panels) and the numbers of identified spectra (Figures 2A and B, middle 
panels) were somewhat greater in most of the crude ECM preparations as compared with the 
corresponding urea-soluble extracts (Supplementary Table S1B and 1C). However, the numbers of 
ECM proteins confidently identified were mostly similar (Figures 2A and B, lower panels, and 
Supplementary Table S1B and 1C), although urea-soluble preparations of normal and diseased 
omentum generally gave a higher number of ECM proteins compared with crude ECM preparations. 
This might be explained by the low content of fibrillar ECM in this tissue (Figure 1A).  
 
We next sought to analyze the composition of the urea-insoluble protein fraction (Supplementary 
Figure S1A and Supplementary Table S1B) and observed that only four proteins were detected solely 
in the pellet and not in either urea-soluble or crude ECM preparations (namely, AMBP and LMAN1L, 
which is in fact a transmembrane protein, in TNBC-adjacent breast tissue and COL6A5 and MFAP2 in 
TNBC samples) (Supplementary Figure S1B and Supplementary Table S1B). However, the total 
number of matrisome proteins detected in the pellet was less than either the crude or urea-soluble 
preparations. It is possible that with more extensive analysis, including peptide-fractionation (see 
below), these proteins would also be detected in the urea-soluble and/or crude ECM preparations. 
Therefore, in general, both crude and urea- soluble extractions result in similar numbers of ECM 
proteins detected, although one method may be superior to the other depending on the tissue and in 
particular, depending on the collagen content of the tissue. 
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Optimization of methods to fractionate ECM-protein-derived peptides 
We have previously reported that off-line fractionation of peptide mixtures by off-gel electrophoresis 
increased by a factor of 3 the number of matrisome peptides confidently identified, which resulted in 
the identification of twice as many core ECM components and over 10 times the number of matrisome-
associated proteins 8.  Off-gel electrophoresis is a lengthy process, and is now being replaced in 
proteomic pipelines by fractionation using high-pH liquid chromatography (also termed basic-reversed-
phase or bRP-LC), orthogonal to the LC separation in-line with the tandem mass spectrometry. We 
sought to determine whether fractionation by bRP-LC was beneficial to identify otherwise undetected 
ECM proteins from both urea-soluble and crude ECM preparations. Independent of the tissue type or 
the method employed to digest ECM-enriched samples into peptides, fractionation prior to LC-MS/MS 
resulted in the identification of a greater number of spectra and proteins (Figure 3 and Supplementary 
Table S1D). In the case of omental samples, the urea-soluble preparation, when coupled with bRP-LC 
fractionation, consistently resulted in higher numbers of ECM proteins detected when compared to 
fractionated crude preparations (Figure 3A).  This is presumably a consequence of the reduced amount 
of collagens in the urea-soluble fraction (Supplementary Table S1D). Furthermore, peptide 
fractionation was particularly beneficial to identify lower-abundance matrisome-associated proteins 
such as ECM-affiliated proteins and ECM regulators (including ECM cross-linking enzymes or 
proteases) (Figure 3B and 3C and Supplementary Table S1D).   
 
Importance of allowing for proline hydoxylations for in silico protein identification 
Peptide and subsequent protein identification from tandem mass spectrometry data rely on the 
comparison of experimental spectral mass values with databases containing theoretical spectral data. It 
is important that search algorithms include post-translational modifications (PTMs) that alter the mass 
of amino acids. Hydroxylation of prolines and lysines are obligate PTMs of triple-helical collagens 
(prolines represent 17% of amino acids in collagen I) and other ECM proteins 25–27. However, these 
PTMs are not routinely included when interrogating databases for protein identification because they 
increase the search time. To examine the significance of including the dynamic modifications of lysine 
and proline hydoxylation, we selected a dataset and conducted a database search in four different 
ways: without allowing for lysine or proline hydroxylation; allowing only lysine hydroxylation; 
allowing only proline hydroxylation, or allowing both lysine and proline hydroxylation. Allowing for 
proline hydroxylations (and to a lesser extent for lysine hydroxylations) led to a significant increase of 
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the number of identified spectra of matrisome proteins by factor of 2 (Figure 4A, left panels), as also 
previously reported by	Barallobre-Barreiro and collaborators28, and thus to a more accurate estimation 
of the abundance of matrisome proteins (Figure 4B, left panel). Allowing these PTMs also allowed the 
identification of several additional ECM proteins (Figure 4C, left panel, and Supplementary Table S1E 
and 1F). Importantly, allowing for these two PTMs was equally beneficial to the analysis of urea-
soluble and crude ECM extracts. Of note, these two PTMs, did not increase significantly the number of 
spectra or unique peptides of non-matrisome proteins (Figure 4A-C, right panels). Therefore, allowing 
for proline and lysine hydroxlations is beneficial specifically for the detection of ECM proteins and we 
recommend they be included. 
 
Scripts to annotate matrisome proteins and calculate mass-spectrometric metrics 
In order to facilitate the annotations of matrisome proteins in large datasets, we developed a script 
called "Matrisome Annotator". Providing that a dataset contains Entrez or HUGO gene symbols for 
each entry, the script will return an output file in which each entry will be annotated as being part of the 
matrisome or not, and will be tagged with matrisome division (core matrisome vs. matrisome-
associated) and category (ECM glycoproteins, collagens, proteoglycans, ECM-affiliated proteins, ECM 
regulators or secreted factors). "Matrisome Annotator" can be used to annotate not only proteomic data 
but any kind of list of genes/proteins. We also developed a second script, called "Matrisome Analyzer", 
that calculates the proportion of ECM content in terms of number of spectra, number of unique 
peptides, number of proteins and peptide intensity (i.e. protein abundance) in proteomics dataset. This 
script allows rapid evaluation of the abundance of matrisome vs. non-matrisome proteins in any given 
dataset input as a delimited text file, and exports the calculation in tables and graphs. Both scripts are 
available as webtools and to download under the Analytical Tools section of the Matrisome Project 
website (http://matrisome.org/).  
 [Note to the editor and reviewers: the "Analytical Tools" section of the website is password protected 
during the evaluation of the manuscript and will be made publicly available upon acceptance of the 
manuscript. To access the pages, log in to the website using the login button located on the upper right 
corner of the website with the following credentials: login: reviewer; password: matrisome. The 
Analytical tools" section will appear on the left menu with two sub-pages "Matrisome Annotator" and 
"Matrisome Analyzer". We have provided detailed description of the scripts and user manual on the 
dedicated web pages].   
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DISCUSSION  
 
We provide here a detailed description of mass-spectrometry-based methods allowing in-depth and 
comprehensive characterization of the composition of ECM of normal and diseased tissues. The major 
advantage of these methods is that each step, from the solubilization of ECM proteins to the 
interpretation of mass spectrometric data, has been optimized to take into account biochemical 
characteristics of ECM and ECM-associated proteins. For example, we recommend allowing for 
proline and lysine hydroxylation when searching databases, as this significantly increases ECM protein 
detection and identification. The preferred method to solubilize ECM-enriched protein samples for 
digestion to peptides depends on the tissue and its ECM content and, in some cases, restricting the 
analysis to urea-soluble ECM proteins, permits detection of additional proteins. This is because 
significant proportions of the collagens remain insoluble. Few proteins are missed by ignoring the urea-
insoluble fraction, although of course, the relative amounts of proteins detected are altered, which 
compromises semi-quantitative conclusions. Furthermore, inclusion of a pre-fractionation step by bRP-
LC chromatography provides an alternative means, allowing detection of additional proteins. It is 
worth noting that high pH reversed-phase peptide fractionation can be achieved using commercially 
available spin columns requiring only a bench centrifuge. In addition, any number of fractions can be 
generated depending on the complexity of the samples and the desired coverage. 
Although not discussed in the manuscript, these methods can be coupled to label-based quantitative 
proteomics 29, which allows quantification of the abundance of proteins and peptides in different 
samples, and also allows multiplexing, thus reducing mass-spectrometer time.  
 
CONCLUSION 
 
Alterations in the composition and organization of the ECM cause or accompany the development of 
diseases such as fibrosis, cardio-vascular diseases, musculo-skeletal diseases, and cancers.   
The application of the proposed methods to profile the composition of the ECM of, for example, pairs 
of normal vs. diseased tissues, treated vs. untreated tissues, or poorly vs. highly metastatic tumors, or 
cell or organoid cultures can lead to the identification of novel ECM proteins that could serve as 
prognostic or diagnostic biomarkers or novel therapeutic targets.  
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SUPPORTING INFORMATION 
 
• Supplementary Table S1: Complete mass spectrometry dataset. 
• Supplementary Figure S1: Composition of urea-insoluble protein samples. 
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Figure	1.	Experimental	pipeline
A. Masson’s	trichrome staining	(blue)	highlight	fibrillar collagen	content	of	the	four	tissues	profiled	in	this	study.	
B.	Experimental	pipeline.	Description	of	the	samples	analyzed	in	this	study	is	presented	Supplementary	Table	S1A.
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Figure 2. Comparison of matrisome and non-matrisome proteins identified in urea-soluble vs. crude ECM samples.
Bar charts represent the distribution of matrisome (blue) vs. non-matrisome (grey) proteins in terms of peptide
abundance (upper panels), number of spectra (middle panels), and number of proteins (lower panels) in urea-soluble
or crude ECM extracts from normal omental tissue and omental metastases from ovarian tumors (A) and normal
breast tissues and triple-negative breast tumors (B). Two independent samples were compared for each tissue and
methodology. Link to Supplementary Tables S1B and S1C.
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Figure	3.	Peptide	fractionation	increases	the	number	of	ECM	and	ECM-associated	proteins	identified	by	mass	
spectrometry	in	both	urea-soluble	and	crude	ECM	samples.
A. Bar charts represent the number of matrisome proteins identified proteins in urea-soluble or ECM samples from
normal omentum (left) or omental metastasis from ovarian cancer (right) fractionated or not by basic-reverse phase
liquid chromatography prior to LC-MS/MS. B - C. Bar charts represent the number of identified spectra corresponding
to core matrisome (B) or matrisome-associated (C) proteins in urea-soluble or ECM samples from normal omentum
(left) or omental metastasis from ovarian cancer (right) fractionated or not by basic-reverse phase liquid
chromatography prior to LC-MS/MS. Link to Supplementary Tables S1C and S1D.
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Figure 4. Importance of allowing hydroxylation of prolines when searching databases to identify and quantify ECM
proteins
Bar charts represent the number of spectra (A), peptide abundance (B), and number of proteins (C) for matrisome
(left) and non-matrisome (right) proteins identified by searching the data allowing or not for prolines and/or lysines
hydroxylations as dynamic modifications. Post-fractionation data to conduct this comparative analysis were acquired
on urea-soluble or crude ECM extracts from omental metastasis from high-grade-serous ovarian cancer.
Link to Supplementary Tables S1E and S1F.
A.	
B.	
C.	
CHARACTERIZATION OF THE EXTRACELLULAR MATRIX  
OF NORMAL AND DISEASED TISSUES USING PROTEOMICS 
Alexandra Naba1¶#*, Oliver M. T. Pearce2#*, Amanda Del Rosario3, Duanduan Ma4, Huiming 
Ding4, Vinothini Rajeeve2, Pedro R. Cutillas2, Frances R. Balkwill2+, Richard O. Hynes1, 5+ 
1 Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; 
Cambridge, MA, U.S.A 
2 Barts Cancer Institute, Queen Mary University of London, London, UK 
3 Proteomics Core Facility, Koch Institute for Integrative Cancer Research, Massachusetts Institute 
of Technology; Cambridge, MA, U.S.A 
4 Bioinformatics and Computing Facility, Koch Institute for Integrative Cancer Research, 
Massachusetts Institute of Technology; Cambridge, MA, U.S.A 
5 Howard Hughes Medical Institute, Massachusetts Institute of Technology; Cambridge, MA, 
U.S.A 
¶ Present address: Department of Physiology and Biophysics, University of Illinois at Chicago, 
Chicago, IL, U.S.A 
# These authors contributed equally to this work. 
+ These authors share senior authorship of the paper.
* Corresponding authors:
Alexandra Naba 
anaba@uic.edu 
Phone: +1 312-355-5417 
Oliver Pearce 
o.pearce@qmul.ac.uk
Phone: +44 (0) 207882 3591 
 Supplementary Information - Table of content: 
- Supplementary Table S1 Legend
- Supplementary Figure S1
S1
Supplementary Table 1: Complete mass spectrometry dataset 
A. Samples analyzed, methods employed, and associated raw spectrum file names.
B. Complete dataset of the analysis of unfractionated peptides from crude ECM, urea-soluble ECM, and
urea-insoluble ECM enriched from triple-negative breast tumors or adjacent breast tissue from two 
patients. Data are sorted by samples and then matrisome categories. 
C. Complete dataset of the analysis of unfractionated peptides from crude ECM, urea-soluble ECM, and
urea-insoluble ECM enriched from omental metastases from high-grade-serous-ovarian-cancer patients 
or normal omental tissue from low-grade ovarian cancer patients. Data are sorted by samples and then 
matrisome categories. 
D. Complete dataset of the analysis of fractionated peptides from crude ECM and urea-soluble ECM
enriched from high-grade-serous-ovarian-cancer omental metastases high-grade-serous-ovarian-cancer 
patients or normal omental tissue from low-grade ovarian cancer patients. Data are sorted by samples 
and then matrisome categories. 
E. Table summarizes mass spectrometric metrics (peptide intensity reflecting protein abundance, number
of spectra, number of unique peptides and number of proteins) calculated for ECM and non-ECM 
proteins identified in urea-soluble or crude ECM-enriched sample from one ovarian omental metastasis 
when allowing or not for proline and/or lysine hydroxylations when conducting database search (related 
to Figure 4D). 
F. List of proteins identified in urea-soluble or crude ECM-enriched sample from one ovarian omental
metastasis when allowing or not for proline and/or lysine hydroxylations when conducting database 
search. * indicates that at least two isoforms were detected for this gene. 
S2
Supplementary	Figure		S1:	Composition	of	urea-insoluble	protein	samples
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A. Bar	chart	represents	the	distribution	of	matrisome	(blue)	vs.	non-matrisome	(grey)	proteins	in	urea-
insoluble	ECM	samples	from	from	ovarian	tumors	(left)	and	normal	breast	tissues	and	triple-negative	breast
tumors.	Two	2	independent	samples	were	compared	for	each	tissue	and	methodology	(#1	and	#2).
B. Venn	diagrams	represent	the	overlap	of	ECM	proteins	detected	by	mass	spectrometry	when	processing
the	samples	according	to	one	of	the	three	methods	described	in	the	manuscript.
See	Supplementary	Table	S1B.
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